Topic:
Blockbusters
Latest Headlines
Latest Headlines
AARP fears Pfizer tactics to defend Lipitor could become model
A new AARP study worries that Pfizer's aggressive use of price hikes, pay-for-delay deals, and discounts and coupons when Lipitor faced generic competition will become the blueprint for the industry.
Top 10 Cardio Drugs 2012
Last year, the top 10 cardio drugs racked up sales of $28.644 billion, down 23% from the $37.271 billion they sold in 2011. Still, the group has made a lot of money for its companies for years and, in some cases, completely changed the treatment of heart disease. It is an interesting list. Only Merck has two drugs in the top 10. Read the report >>
Lagging Januvia weighs on Merck's none-too-pretty first quarter
Nothing spoke more loudly today of Merck's current worries than its new $15 billion stock-buyback program. But with sales suffering from Singulair generics, an unexpected shortfall in Januvia sales, and a series of recent R&D disappointments to its credit, Merck needs all the investor-relations help it can get.
Which drugs are the biggest duds in blockbuster-land?
EvaluatePharma researchers totted up sales for the last 5 years' worth of analysts' blockbuster picks--and found plenty of bad bets.
Rose-colored glasses off for many of 2012's new drugs, report shows
EvaluatePharma has an antidote to any starry-eyed thinking about new drug launches. According to EP Vantage's new state-of-the-industry report, many of last year's rollouts are already disappointments, at least compared with previous sales projections.
Novo, Sanofi duke it out in diabetes market
As new diabetes drug Tresiba inches its way toward approval, Novo Nordisk and rival Sanofi have put up dueling studies and generated dueling headlines. But their rivalry extends beyond those two headlining drugs, Bloomberg reports.
UPDATED: Novartis has a win some, lose some day with Gleevec
Novartis and its cancer drug Gleevec had one of those days that starts off not looking so good and then something comes along to turn things around.
With FDA panel vote, J&J diabetes threat looms for Merck's Januvia
Johnson & Johnson nabbed an FDA committee's support for its new diabetes drug, canaglifozin, now dubbed Invokana. That's good for J&J, of course. It's not so good for Merck, whose Januvia franchise would be directly in Invokana's sights.
AbbVie CFO sees no need for big acquisition
At the J.P. Morgan Healthcare Conference on Tuesday, AbbVie CFO Bill Chase swept aside suggestions that the new company needed some big acquisition to move forward despite the fact that it is now on its own in the world and essentially living off one product, anti-inflammatory Humira.
Military drug sales amp up with rise in new veterans, retirees
With the growing ranks of aging veterans--and growing use of chronic meds by younger veterans--the Pentagon's spending on drugs has skyrocketed, with $2.7 billion in spending on antidepressants alone.
